ETANA INTRODUCES TWO INNOVATIVE CANCER THERAPY PRODUCTS IN INDONESIA
Jakarta, April 12, 2025 - PT Etana Biotechnologies Indonesia (Etana) introduced two new products in collaboration with global partner BeiGene (tislelizumab) and BRUKINSA® (zanubrutinib) during the Etana Oncology Summit, which also served as a scientific forum to discuss the latest advancements in cancer therapies.
The event, held at Sheraton Hotel Gandaria City, Jakarta, was attended by prominent figures in the field of oncology, including Prof. Dr. dr. Ary Harryanto Reksodiputro and Dr. dr. Tubagus Djumhana Atmakusuma from the Indonesian Society of Hematology and Medical Oncology (ISHMO) and the Indonesian Society of Hematology and Transfusion Medicine (ISHTM).
“The launch of ETAPIDI® and BRUKINSA® marks a significant milestone in Etana's commitment to providing innovative cancer therapies in Indonesia. We believe the presence of ETAPIDI® and BRUKINSA® will bring new hope to cancer patients in Indonesia — by offering innovative therapies grounded in global medical advancements, yet locally accessible and more affordable,” said Nathan Tirtana, President Director of Etana.
“BeiGene, in collaboration with Etana, aims to accelerate research and deliver more affordable products for global patients. The launch of these two cancer therapy products is expected to improve access and affordability for the public. Moving forward, we hope to further develop research and carry out technology transfers with biopharmaceutical companies in Indonesia,” stated Dr. Xiaobin Wu, President & Chief Operating Officer of BeiGene.
The Etana Oncology Summit not only served as a product launch platform but also reinforced collaboration between industry players and medical professionals to enhance the quality of cancer care services.
“We highly value the outstanding contributions of doctors and medical personnel who are on the front lines of diagnosing and supporting patients,” added Nathan.
Through this initiative, Etana reaffirms its mission to provide impactful healthcare solutions for patients across Indonesia. Etana is recognized as a local biopharmaceutical company dedicated to delivering innovative and affordable healthcare solutions to the Indonesian people, particularly in the areas of cancer therapy and other critical diseases.
About Etana
Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.
Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.